AstraZeneca-Merck's Lynparza wins EU panel recommendation for cancer treatments
In This Article:
Sept 21 (Reuters) - A European regulatory panel has recommended the approval of Lynparza, a blockbuster cancer treatment developed by AstraZeneca Plc and Merck & Co Inc, to treat two separate forms of cancer.
The European Medicines Agency recommended Lynparza for patients with a form of prostate cancer and as a first-line maintenance treatment for a form of advanced ovarian cancer, AstraZeneca added. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Saumyadeb Chakrabarty)
Terms and Privacy Policy